Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What Happened

Key Points

• Telix shares fell sharply at the open, dropping from a $12.42 close to $11.34 before last trading at $11.36.
• The company reported strong first-half results, with revenue up 22% year over year to $477 million and adjusted EBITDA rising 146%; management also highlighted continued investment in cancer programs and manufacturing expansion.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $20.40 target price, although recent downgrades—including RBC’s move to “sector perform”—have added near-term pressure.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report)'s stock price gapped down prior to trading on Friday . The stock had previously closed at $12.42, but opened at $11.34. Telix Pharmaceuticals shares last traded at $11.36, with a volume of 68,628 shares.

Telix Pharmaceuticals News Roundup

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Telix reported first-half revenue of $477 million, up 22% year over year, while adjusted EBITDA increased 146%. Precision Medicine revenue rose 27%, supported by Illuccix and Gozellix, and manufacturing revenue reached $146 million. Telix Pharmaceuticals Limited stock EBITDA and revenue report
• Positive Sentiment: Management highlighted continued investment in prostate, kidney and brain cancer programs, including $124 million of research and development spending, while expanding its global manufacturing footprint and advancing its late-stage pipeline. Telix 2026 half-year results
• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and set a $22 price target, implying substantial upside based on the cited reference price. Quarterly earnings per share also exceeded consensus estimates. Wedbush rating report
• Neutral Sentiment: Telix is attracting increased discussion on HotCopper alongside other Australian-listed companies. The heightened attention may increase trading activity but does not represent a fundamental change in the investment case. HotCopper Telix investor attention
• Negative Sentiment: Telix shares were downgraded by an analyst, creating near-term pressure even though other brokers remain positive. The downgrade may reflect valuation, execution or expectations concerns following the company’s strong run and results. Why Telix shares were downgraded

Analysts Set New Price Targets

TLX has been the subject of several recent research reports. Wedbush restated an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Thursday. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Tuesday, July 7th. Weiss Ratings reiterated a "sell (d)" rating on shares of Telix Pharmaceuticals in a research note on Friday, July 17th. Citigroup reissued a "buy" rating on shares of Telix Pharmaceuticals in a research report on Thursday. Finally, Royal Bank Of Canada lowered Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Telix Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $20.40.

Telix Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The business's 50 day moving average is $10.93 and its two-hundred day moving average is $9.64.

Institutional Investors Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. bought a new stake in Telix Pharmaceuticals during the 2nd quarter valued at approximately $1,731,000. Private Advisor Group LLC boosted its stake in Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock worth $1,669,000 after purchasing an additional 128,070 shares during the period. XTX Topco Ltd bought a new position in Telix Pharmaceuticals in the 4th quarter worth approximately $89,000. Quadrature Capital Ltd purchased a new stake in Telix Pharmaceuticals during the 4th quarter valued at approximately $276,000. Finally, OLD Mission Capital LLC purchased a new stake in Telix Pharmaceuticals during the 4th quarter valued at approximately $111,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source